453 related articles for article (PubMed ID: 28984175)
1. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
Wang H; Wang M; Wei J; Wang L; Mao L; Jin J
J Int Med Res; 2018 Feb; 46(2):883-894. PubMed ID: 28984175
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma].
Huang HW; Jiang YB; Fu TW; Xu T; Chen XC; Jin ZM; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):602-6. PubMed ID: 27535862
[TBL] [Abstract][Full Text] [Related]
4. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency.
Shenkier TN; Voss N; Chhanabhai M; Fairey R; Gascoyne RD; Hoskins P; Klasa R; Morris J; O'Reilly SE; Pickles T; Sehn L; Connors JM
Cancer; 2005 Mar; 103(5):1008-17. PubMed ID: 15651059
[TBL] [Abstract][Full Text] [Related]
5. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
[TBL] [Abstract][Full Text] [Related]
7. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
8. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.
Chen C; Sun P; Cui J; Yan S; Chen H; Xia Y; Bi X; Liu P; Wang Y; Yang H; Nie M; Zhang XW; Jiang W; Li ZM
Cancer Med; 2019 Apr; 8(4):1359-1367. PubMed ID: 30821418
[TBL] [Abstract][Full Text] [Related]
9. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
[TBL] [Abstract][Full Text] [Related]
10. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
[TBL] [Abstract][Full Text] [Related]
11. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
[TBL] [Abstract][Full Text] [Related]
13. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
Qian L; Zhou C; Shen J; Cen J; Yin W
Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
[TBL] [Abstract][Full Text] [Related]
14. [Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
Li QC; Yuan XL; Wang YF; Zou DH; Zhao YZ; Qiu LG
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):254-7. PubMed ID: 18361837
[TBL] [Abstract][Full Text] [Related]
15. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
[TBL] [Abstract][Full Text] [Related]
16. Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.
Kaji FA; Martinez-Calle N; Bishton MJ; Figueroa R; Adlington J; O'Donoghue M; Smith S; Byrne P; Paine S; Sovani V; Auer D; James E; Bessell EM; Grainge MJ; Fox CP
Br J Haematol; 2021 Nov; 195(4):561-570. PubMed ID: 34368948
[TBL] [Abstract][Full Text] [Related]
17. R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma.
Ferreri AJM; Calimeri T; Conte GM; Cattaneo D; Fallanca F; Ponzoni M; Scarano E; Curnis F; Nonis A; Lopedote P; Citterio G; Politi LS; Foppoli M; Girlanda S; Sassone M; Perrone S; Cecchetti C; Ciceri F; Bordignon C; Corti A; Anzalone N
Blood; 2019 Jul; 134(3):252-262. PubMed ID: 31118164
[TBL] [Abstract][Full Text] [Related]
18. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
20. Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.
Malecek MK; Petrich AM; Rozell S; Chu B; Trifilio S; Galanina N; Maurer M; Farooq U; Link BK; Nowakowski GS; Nabhan C; Ayed AO
Am J Hematol; 2017 Nov; 92(11):1156-1162. PubMed ID: 28719025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]